Physiogenex will be presenting its two obese/type 2 diabetic rat models of nephropathy at the 59th ERA congress in Paris France May 19-22th, 2022.
The first abstract is entitled “THE LUND METS RAT, AN OBESE TYPE 2 DIABETIC PRECLINICAL MODEL, DEVELOPS NON-ALCOHOLIC STEATOHEPATITIS, DIABETIC NEPHROPATHY AND HEART FAILURE WITH PRESERVED EJECTION FRACTION UNDER HIGH FAT/CHOLESTEROL/FRUCTOSE DIET”.
The second abstract is entitled “LIRAGLUTIDE IMPROVES BOTH DIABETIC NEPHROPATHY AND CARDIOMYOPATHY IN THE SDT FATTY RAT, A CARDIORENAL MODEL OF TYPE 2 DIABETES”.
Both abstracts will be presented as mini-oral presentations by Dr. François Briand, Director of Research and Business Development, on Thursday May the 19th, during the Diabetes – Basic research sessions from 08:00am-12:45pm on May the 19th.
Physiogenex is a leading preclinical research organization providing non clinical services in metabolic disorders and complications.
We offer in vivo translational diseases models as well as ex vivo assays to support efficacy and pharmacological assays. We have a strong expertise on metabolic diseases, diabetes, insulin resistance, obesity, dyslipidemia, liver diseases (NASH to fibrosis), cardiovascular and renal complications.